AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18669787 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchanger
Number of subjects: 16
Study 15933397 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 0
Study 15933397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15933397 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative binomial regression models
Number of subjects: 0
Study 14523700 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strength training (A&ST) group
Number of subjects: 40
Study 14523700 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training only (ATO) group
Number of subjects: 40
Study 10735983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (4 Hz)
Number of subjects: 30
Study 10735983 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS (110 Hz)
Number of subjects: 30
Study 10735983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 10735983 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 8695076 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alfentanil (ALF) 10 mcg/kg
Number of subjects: 40
Study 8695076 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia using plain lidocaine (XYL)
Number of subjects: 40
Study 8695076 — intervention group
Group type: EXPERIMENTAL
Intervention: IV thiopental sodium (TPL) 1.5 mg/kg
Number of subjects: 40
Study 8695076 — intervention group
Group type: EXPERIMENTAL
Intervention: IV esmolol (ESM) 1 mg/kg
Number of subjects: 40
Study 1514331 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine 100 mg 2 min before tracheal intubation
Number of subjects: 193
Study 1514331 — intervention group
Group type: COMPARATOR
Intervention: No spray (Control)
Number of subjects: 193
Study 6476334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 20
Study 6476334 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg ketamine
Number of subjects: 20
Study 30927644 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation with vitamin C (500 mg/d) and E (400 UI/d) for 15 days
Number of subjects: 21
Study 30927644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 29991707 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PgE1) therapy
Number of subjects: 30
Study 29991707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PgE1 and endothelin‐1 blocker (bosentan)
Number of subjects: 30
Study 29991707 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study 28545574 — intervention group
Group type: EXPERIMENTAL
Intervention: INCLUSIVE multi‐component intervention including a social and emotional learning curriculum, changes to school environment, and staff training in restorative practice.
Number of subjects: 6667
Study 28545574 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (control group).
Number of subjects: 6667
Study 28545574 — intervention group
Group type: EXPERIMENTAL
Intervention: INCLUSIVE multi‐component intervention.
Number of subjects: 6667
Study 25593496 — intervention group
Group type: EXPERIMENTAL
Intervention: BOACT group (240 mg bismuth subcitrate, 20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, 500 mg tinidazole)
Number of subjects: 208
Study 25593496 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTMO group (240 mg bismuth subcitrate, 20 mg omeprazole, 500 mg tetracycline, 500 mg metronidazole, 200 mg ofloxacin)
Number of subjects: 208
Study 25593496 — intervention group
Group type: EXPERIMENTAL
Intervention: BOACT group
Number of subjects: 208
Study 25593496 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTMO group
Number of subjects: 208
Study 22764197 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg daily for 12 weeks)
Number of subjects: 80
Study 22764197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21577221 — intervention group
Group type: COMPARATOR
Intervention: Arbaclofen placarbil (AP) 20 mg
Number of subjects: 0
Study 21577221 — intervention group
Group type: COMPARATOR
Intervention: Arbaclofen placarbil (AP) 30 mg
Number of subjects: 0
Study 21577221 — intervention group
Group type: COMPARATOR
Intervention: Combined Arbaclofen placarbil (AP) 20/30 mg
Number of subjects: 0
Study 21577221 — intervention group
Group type: COMPARATOR
Intervention: Arbaclofen placarbil (AP) 10 mg
Number of subjects: 0
Study 17964767 — intervention group
Group type: EXPERIMENTAL
Intervention: PS/DAG oil
Number of subjects: 61
Study 17964767 — intervention group
Group type: COMPARATOR
Intervention: TAG (control)
Number of subjects: 61
Study 17964767 — intervention group
Group type: COMPARATOR
Intervention: DAG
Number of subjects: 61
Study 16580899 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg daily)
Number of subjects: 51
Study 16580899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg 4 times per day)
Number of subjects: 51
Study 16580899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12951544 — intervention group
Group type: EXPERIMENTAL
Intervention: STD treatment interventions
Number of subjects: 0
Study 12951544 — intervention group
Group type: COMPARATOR
Intervention: Community-based randomised controlled trials of STD interventions
Number of subjects: 0
Study 11112003 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous retrograde warm blood reperfusion
Number of subjects: 42
Study 11112003 — intervention group
Group type: COMPARATOR
Intervention: No reperfusion (control)
Number of subjects: 42
Study 9132328 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Jaccoud's syndrome (5 out of 23, 21.7%)
Number of subjects: 23
Study 9132328 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients meeting diagnostic criteria for SLE in the Jaccoud group (80%)
Number of subjects: 23
Study 9132328 — intervention group
Group type: COMPARATOR
Intervention: Patients without Jaccoud's syndrome
Number of subjects: 23
Study 7522798 — intervention group
Group type: EXPERIMENTAL
Intervention: 127I-labeled peptides tested for their ability to displace 125I-T4 binding to thyroid hormone autoantibodies (THAA) in Graves' disease cases.
Number of subjects: 2
Study 7522798 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I-labeled peptides tested for direct binding to antibodies.
Number of subjects: 2
Study 7522798 — intervention group
Group type: COMPARATOR
Intervention: hTg obtained from a normal thyroid gland (NTg) and a case of Hürthle cell adenoma (CTg) tested for 125I-T4 binding displacement.
Number of subjects: 2
Study 3028892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L‐3H‐NA
Number of subjects: 16
Study 3028892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3H‐isoproterenol
Number of subjects: 16
Study 3028892 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐3H‐noradrenaline infusion
Number of subjects: 16
Study 27820726 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 27
Study 27820726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 26852075 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75mg/m2 + Abiraterone Acetate 1000mg + Prednisone 10mg
Number of subjects: 22
Study 24369912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein/low-GI diet (LP/LGI)
Number of subjects: 938
Study 24369912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein/high-GI diet (LP/HGI)
Number of subjects: 938
Study 24369912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/low-GI diet (HP/LGI)
Number of subjects: 938
Study 24369912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/high-GI diet (HP/HGI)
Number of subjects: 938
Study 24369912 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 938
Study 24369912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (initial phase)
Number of subjects: 938
Study 22062334 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance yield markings and pedestrian crosswalk prompt signs
Number of subjects: 0
Study 22062334 — intervention group
Group type: COMPARATOR
Intervention: Standard markings
Number of subjects: 0
Study 19757354 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid-liposome eye spray (Tears Again)
Number of subjects: 216
Study 19757354 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronate artificial tears (Vismed light)
Number of subjects: 216
Study 18941964 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted clinical education on borderline personality disorder
Number of subjects: 99
Study 18941964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 99
Study 16413604 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline treatment
Number of subjects: 24
Study 16413604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12637483 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary treatment
Number of subjects: 2306
Study 12637483 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary function and bother
Number of subjects: 2306
Study 12637483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual function and bother
Number of subjects: 2306
Study 10672286 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 46
Study 10672286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46
Study 10672286 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 46
Study 8542001 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education intervention
Number of subjects: 383
Study 8542001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 383
Study 2064149 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic antiemetic prophylaxis (metilpednisolone 4 mg/Kg/dose/iv 2 doses; metodopamide 0.5 mg/Kg/dose/iv 4 doses; diphenydramine 1 mg/Kg/dose/iv 4 doses)
Number of subjects: 24
Study 2064149 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic antiemetic prophylaxis
Number of subjects: 24
Study 6796712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vamin and Intralipid
Number of subjects: 122
Study 6796712 — intervention group
Group type: COMPARATOR
Intervention: Travasol and hypertonic dextrose
Number of subjects: 122
Study 31525358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 68
Study 29191262 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiday training on evidence-based decision making
Number of subjects: 12
Study 29191262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study 24740935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 46
Study 24740935 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (NP)
Number of subjects: 46
Study 23803895 — intervention group
Group type: COMPARATOR
Intervention: Lipid (pure lipid condition, L3)
Number of subjects: 20
Study 23803895 — intervention group
Group type: COMPARATOR
Intervention: Protein (pure protein condition, P3)
Number of subjects: 20
Study 23803895 — intervention group
Group type: COMPARATOR
Intervention: 2:1 lipid:protein combination (L2P1)
Number of subjects: 20
Study 23803895 — intervention group
Group type: COMPARATOR
Intervention: 1:2 lipid:protein combination (L1P2)
Number of subjects: 20
Study 23803895 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 17625308 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term infusion of gabexate (12 hours)
Number of subjects: 0
Study 17625308 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term infusion of gabexate (2.5 and 6.5 hours)
Number of subjects: 0
Study 17625308 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term administration of ulinastatin (10 minutes)
Number of subjects: 0
Study 17625308 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term infusion of gabexate
Number of subjects: 0
Study 17625308 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term administration of ulinastatin
Number of subjects: 0
Study 15264730 — intervention group
Group type: EXPERIMENTAL
Intervention: Suntouch radiant warming
Number of subjects: 60
Study 15264730 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming
Number of subjects: 60
Study 11421841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Number of subjects: 51
Study 11421841 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine, 2 mg x ml(‐1) with continuous infusion of 6 ml x h(‐1) and PCEA bolus doses of 2 ml
Number of subjects: 51
Study 9284428 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and beta blockers
Number of subjects: 0
Study 9284428 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers and ACE inhibitors
Number of subjects: 0
Study 8491972 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position during 2nd stage of labour
Number of subjects: 200
Study 8491972 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position during delivery
Number of subjects: 200
Study 8491972 — intervention group
Group type: COMPARATOR
Intervention: Supine position during delivery
Number of subjects: 200
Study 8491972 — intervention group
Group type: COMPARATOR
Intervention: Control group (supine position)
Number of subjects: 200
Study 8491972 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting group
Number of subjects: 200
Study 3126699 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (25 ml daily)
Number of subjects: 64
Study 3126699 — intervention group
Group type: COMPARATOR
Intervention: Bulk-laxative (8.7 g daily)
Number of subjects: 64
Study 11072596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chicken type II collagen (CII) at 0.25 mg/day (n = 31)
Number of subjects: 60
Study 11072596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 60
Study 11072596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chicken type II collagen (CII)
Number of subjects: 60
Study 31241002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (10 g/day Inulin)
Number of subjects: 62
Study 31241002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g/day Maltodextrin)
Number of subjects: 62
Study 31241002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Calorie restriction)
Number of subjects: 62
Study 31241002 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Weight loss)
Number of subjects: 62
Study 31491682 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue mussel diet (75g blue mussels, 5 days a week)
Number of subjects: 23
Study 31491682 — intervention group
Group type: COMPARATOR
Intervention: Control diet (75g meat, 5 days a week)
Number of subjects: 23
Study 28723835 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified supine position (bed tilted 20° upright with a pillow between feet and the end of the bed)
Number of subjects: 300
Study 26880594 — intervention group
Group type: EXPERIMENTAL
Intervention: TES+TAU
Number of subjects: 507
Study 26880594 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 507
Study 26880594 — intervention group
Group type: EXPERIMENTAL
Intervention: TES+TAU (subgroup not abstinent at study entry)
Number of subjects: 507
Study 25006420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 405
Study 25006420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 25006420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg or 40 mg
Number of subjects: 405
Study 23144810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (<30 ng/mL)
Number of subjects: 2588
Study 23144810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (<20 ng/mL)
Number of subjects: 2588
Study 23144810 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations categorized as <10, 10-20, 20-30, and ≥30 ng/mL
Number of subjects: 2588
Study 23144810 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 2588
Study 20413028 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 1376
Study 20413028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm
Number of subjects: 1376
Study 17419662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive short-term music curriculum targeting reading comprehension and vocabulary skills
Number of subjects: 0
Study 17419662 — intervention group
Group type: COMPARATOR
Intervention: Control class (not specified)
Number of subjects: 0
Study 17419662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive short-term music curriculum
Number of subjects: 0
Study 15752880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular or conformal fields with a dose of 66 Gy
Number of subjects: 197
Study 11907286 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Number of subjects: 1232
Study 11907286 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 1232
Study 11907286 — intervention group
Group type: COMPARATOR
Intervention: Implantable defibrillator vs Conventional medical therapy
Number of subjects: 1232
Study 10436100 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocyst(e)ine level >/= 7.3 micromol/L
Number of subjects: 495
Study 10436100 — intervention group
Group type: COMPARATOR
Intervention: Control group (plasma homocyst(e)ine level < 7.3 micromol/L)
Number of subjects: 495
Study 7776516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 MAC nitrous oxide
Number of subjects: 10
Study 7776516 — intervention group
Group type: COMPARATOR
Intervention: 0.7 MAC sevoflurane
Number of subjects: 10
Study 7776516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 MAC nitrous oxide after induction of anesthesia
Number of subjects: 10
Study 2130078 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Diazepam
Number of subjects: 14
Study 2130078 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate and Promethazine
Number of subjects: 14
Study 288172 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 273
Study 288172 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 273
Study 288172 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 273
Study 288172 — intervention group
Group type: COMPARATOR
Intervention: General health survey with mass miniature chest X‐ray
Number of subjects: 273
Study 29397659 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus docetaxel (DS)
Number of subjects: 153
Study 29397659 — intervention group
Group type: COMPARATOR
Intervention: S‐1 plus cisplatin (SP)
Number of subjects: 153
Study 27632195 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks worn during the recovery period
Number of subjects: 12
Study 27632195 — intervention group
Group type: COMPARATOR
Intervention: No compression socks worn during the recovery period (control)
Number of subjects: 12
Study 27632195 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks worn during the recovery period (for participants with strong beliefs)
Number of subjects: 12
Study 27632195 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks worn during the recovery period (for participants with neutral or negative perceptions)
Number of subjects: 12
Study 25958473 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery and intramyocardial implantation of BMMNC
Number of subjects: 30
Study 25958473 — intervention group
Group type: COMPARATOR
Intervention: CABG surgery only
Number of subjects: 30
Study 24223740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 160
Study 24223740 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 160
Study 21336804 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 7665
Study 21336804 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs or ARBs
Number of subjects: 7665
Study 21336804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 7665
Study 21336804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 7665
Study 21336804 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-platelet drugs
Number of subjects: 7665
Study 21336804 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7665
Study 21336804 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery by-pass grafting (CABG)
Number of subjects: 7665
Study 19289170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) after temporal lobe surgery
Number of subjects: 40
Study 19289170 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-hemispheric surgery
Number of subjects: 40
Study 19289170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 40
Study 19289170 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 40
Study 19289170 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying seizure disorder
Number of subjects: 40
Study 17827861 — intervention group
Group type: EXPERIMENTAL
Intervention: Group smoking cessation intervention based on social cognitive theory
Number of subjects: 225
Study 17827861 — intervention group
Group type: COMPARATOR
Intervention: Routine training (control group)
Number of subjects: 225
Study 17827861 — intervention group
Group type: COMPARATOR
Intervention: Routine training (control group) after 6 months
Number of subjects: 225
Study 15088883 — intervention group
Group type: EXPERIMENTAL
Intervention: LDD (20 mg b.i.d.) + AFS
Number of subjects: 24
Study 15088883 — intervention group
Group type: COMPARATOR
Intervention: Placebo + AFS
Number of subjects: 24
Study 11531834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 3.0 mg m(‐2) daily + cyclosporin 1.25 mg kg(‐1) daily
Number of subjects: 150
Study 11531834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin 5.0 mg kg(‐1) daily
Number of subjects: 150